Phase I Dose-escalation of S 95005 (TAS-102) in Combination With Oxaliplatin in Metastatic Colorectal Cancer

Trial Profile

Phase I Dose-escalation of S 95005 (TAS-102) in Combination With Oxaliplatin in Metastatic Colorectal Cancer

Recruiting
Phase of Trial: Phase I

Latest Information Update: 03 Nov 2017

At a glance

  • Drugs Tipiracil/trifluridine (Primary) ; Bevacizumab; Nivolumab; Oxaliplatin
  • Indications Colorectal cancer
  • Focus Adverse reactions
  • Sponsors Servier
  • Most Recent Events

    • 02 Jun 2017 According to trial design data presented at the 53rd Annual Meeting of the American Society of Clinical Oncology, the results of the dose-escalation part are expected in 2017.
    • 02 Jun 2017 Trial design and recent update (as of Dec 2016) of this phase I study, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
    • 05 Apr 2017 Planned number of patients changed from 54 to 94.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top